In the present study, we evaluated the efficacy of the bioavailable NF-κB inhibitor DMAPT and gemcitabine using a genetically engineered and clinically relevant mouse model of pancreatic cancer. Here, NFKB1 is linked to familial pancreatic carcinoma.